Genmab A/S (STU:GE91) Stock News, Headlines & Updates
Genmab A/S Stock News from GuruFocus
- 1
Jun 28, 2024
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
Business Wire • 2:00am
Jun 27, 2024
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Business Wire • 7:00pm
Jun 03, 2024
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Business Wire • 9:00am
Jun 02, 2024
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
Business Wire • 5:00pm
May 23, 2024
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
Business Wire • 5:00pm
May 21, 2024
Genmab Completes Acquisition of ProfoundBio
Business Wire • 11:00am
May 14, 2024
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
Business Wire • 10:00am
May 03, 2024
Q1 2024 Genmab A/S Earnings Call Transcript
GuruFocus Research • 11:22pm
Apr 29, 2024
- 1
Show
Entries
Headlines
Total 0- 1
No recent news